CJC-1295 With DAC vs Without DAC: Pharmacokinetics & Endocrine Response

Understanding the Drug Affinity Complex (DAC)

For researchers studying Growth Hormone-Releasing Hormone (GHRH) analogues, distinguishing between CJC-1295 With DAC and CJC-1295 Without DAC is critical. The primary difference lies in their structural modifications and resulting pharmacokinetics.

CJC-1295 Without DAC (Modified GRF 1-29)

This variant is a 29-amino acid peptide. Its molecular structure allows it to bind to GHRH receptors to trigger a short, intense spike in GH levels. Its half-life in a physiological medium is roughly 30 minutes. Researchers utilize this variant when studying natural, pulsatile endocrine responses.

CJC-1295 With DAC

The addition of the Drug Affinity Complex (DAC) significantly alters the peptide’s behavior. The DAC allows the peptide to bind to endogenous blood proteins, specifically albumin. This binding protects the peptide from rapid enzymatic degradation, extending its half-life from 30 minutes to up to 8 days.

Comparative Laboratory Applications

In laboratory models, CJC-1295 With DAC is utilized to observe the effects of a continuous, elevated GH bleed over a prolonged period. Conversely, CJC-1295 Without DAC is preferred for studies attempting to mimic the natural, episodic release of GH without prolonged receptor downregulation.

Disclaimer: Reta Peptide Lab supplies these compounds exclusively for scientific evaluation and not for human administration.